Browse
Submit Data
Databases
API
Help

Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

36 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Expression data from FIT-039 or Flavopiridol compound treated HeLa cells

ABSTRACT: FIT-039 is a novel antiviral compound. Antiviral mechanism of FIT-039 is the inhibition of the viral transcription through suppression of the CTD phosphorylation of RNA polymerase II. We used microarrays to evaluated the effect of FIT-039 on host cellular transcriptome, compared with Flavopiridol which is an existing pan-specific CDK9 inhibitor. HeLa cells were incubated with FIT-039 or flavopiridol at the concentration of IC80 for 24 hr, and cellular RNAs were collected and subjected to microarray analysis. The solvent DMSO was used as a negative control.

ORGANISM(S): Homo sapiens

SUBMITTER: Kei IIDA

PROVIDER: E-GEOD-57429 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

ACCESS DATA

Json Xml

Similar Datasets

Expression data from FIT-039 or Flavopiridol compound treated HeLa cells

Project description:FIT-039 is a novel antiviral compound. Antiviral mechanism of FIT-039 is the inhibition of the viral transcription through suppression of the CTD phosphorylation of RNA polymerase II. We used microarrays to evaluated the effect of FIT-039 on host cellular transcriptome, compared with Flavopiridol which is an existing pan-specific CDK9 inhibitor.

2014-07-08 | GSE57429 | GEO

Flavopiridol profiling on A2780

Project description:The effects of the CDK inhibitor Flavopiridol on the A2780 human adenocarcinoma ovary cell line were analysed by gene expression profiling.

2010-07-14 | GSE18504 | GEO

Flavopiridol profiling on A2780

Project description:The effects of the CDK inhibitor Flavopiridol on the A2780 human adenocarcinoma ovary cell line were analysed by gene expression profiling. A2780 cells were treated with Flavopiridol for 6 hours at a dose equal to 5 times the IC50. Untreated A2780 cells were used as a control. Two replicates per treatment.

2010-07-14 | E-GEOD-18504 | biostudies-arrayexpress

Total RNA Pol2 ChIP-seq in mES cells treated with flavopiridol (Cdk9 inhibitor) after DSIF and NELF knockdown

Project description:Recent studies have found that promoter-proximal pausing occurs at most Pol2-regulated genes. DSIF and NELF function as negative elongation factors and promote Pol2 pausing. P-TEFb, whose enzymatic activity lies in the kinase Cdk9, positively regulates the transition into productive elongation by phosphorylating subunits in DSIF, NELF and Pol2. To gain insights into the interplay between these factors in regulating transcriptional pause release, we tested if knockdown of either pausing factor could bypass P-TEFb function. We find that P-TEFb function is still required for transcriptional elongation after DSIF or NELF knockdown. mES cells were infected with a shRNA hairpin to knockdown Spt5, Spt4, NelfE or control. The resulting cells were then treated with flavopiridol (1uM for 60 minutes). DNA was enriched by chromatin immunoprecipitation (ChIP) and analyzed by Solexa sequencing. A sample of whole cell extract was sequenced and used as the background to determine enrichment. ChIP was performed using an antibody against total RNA Pol2 (Rpb1 N-terminus, Santa Cruz sc-899).

2011-01-19 | E-GEOD-26658 | biostudies-arrayexpress

Flavopiridol in Treating Patients With Refractory Cancer

Project description:RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of flavopiridol in treating patients who have refractory cancer.

| 2006388 | ecrin-mdr-crc

Effects of OGA inhibitor PUGNAc on nascent RNA expression in vivo

Project description:We used 4sU incorporation to detect changes in nascent RNA expression in response to the O-GlcNAc aminidase inhibitor PUGNAc. We found that the distribution of 5' promoter proximal RNAs increased nearly as much as those using the known CDK9 inhibitor flavopiridol. The similar distributions between the known elongation inhibitor flavopiridol and the OGA inhibitor suggested that the PUGNAc blocked RNA pol II elongation in vivo.

2024-10-31 | GSE158746 | GEO

CDK inhibitors and flavopiridol profiling on A2780 and MCF7 cells

Project description:This SuperSeries is composed of the following subset Series: GSE18486: CDK inhibitors PHA-848125 and PHA-690509 profiling on A2780 GSE18498: CDK inhibitor PHA-793887 profiling on A2780 GSE18501: CDK inhibitor PHA-848125 gene expression profiling on MCF7 cell line GSE18504: Flavopiridol profiling on A2780 GSE19638: Compounds profiling on MCF7 Refer to individual Series

2010-07-14 | E-GEOD-18552 | biostudies-arrayexpress

Homo sapiens

Project description:Expression data from FIT-039 or Flavopiridol compound treated HeLa cells

| PRJNA246447 | ENA

Quantification of subcellular mRNA kinetics in mouse embryonic stem cells (flavopiridol)

Project description:Quantification of subcellular mRNA kinetics in mouse embryonic stem cells (flavopiridol)

| PRJNA1079216 | ENA

BS-seq and H3K9me2 ChIP-seq in Arabidopsis after flavopiridol (FLA) treatment

Project description:BS-seq and H3K9me2 ChIP-seq in Arabidopsis after flavopiridol (FLA) treatment

| PRJNA956502 | ENA